{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:50:06Z","timestamp":1793213406703,"version":"4.5.0"},"reference-count":284,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) axis have transformed cancer therapy, yet reliable biomarkers for accurately predicting therapeutic benefit remain limited. Peripheral blood biomarkers have emerged as attractive candidates because of their minimally invasive accessibility, feasibility for serial monitoring, and potential to capture dynamic systemic immune responses during treatment. However, their clinical translation has been hindered by inconsistent findings, biological heterogeneity, and the frequent conflation of prognostic associations with true predictive value. Many commonly reported biomarkers, including circulating tumor DNA (ctDNA), blood-based tumor mutational burden (bTMB), inflammatory indices, and conventional serum markers, primarily reflect tumor burden, systemic inflammation, or host physiological status rather than genuine sensitivity to PD-1\/PD-L1 blockade. In contrast, immune cell-derived biomarkers, particularly dynamic indicators of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T-cell activation and immune reinvigoration, offer stronger mechanistic relevance to checkpoint inhibitor responsiveness, although their predictive utility remains highly context dependent. In this review, we critically evaluate peripheral blood biomarkers using a mechanistically informed framework to distinguish predictive from prognostic biomarkers, integrating evidence from tumor-derived biomarkers, immune cell phenotyping, soluble inflammatory mediators, emerging immune repertoire and extracellular vesicle (EV) biomarkers, and composite longitudinal models. We further discuss translational barriers, clinical implementation challenges, and future priorities for biomarker development, aiming to provide a more rigorous framework for biomarker-guided precision immunotherapy.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1924506","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:29:44Z","timestamp":1787826584000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Peripheral blood biomarkers in PD-1\/PD-L1 immunotherapy: distinguishing predictive from prognostic biomarkers"],"prefix":"10.3389","volume":"17","author":[{"given":"Xuejun","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Hematology, Puyang Oilfield General Hospital Affiliated to Henan Medical University","place":["Puyang, Henan, China"]},{"name":"Puyang Cell Therapy Engineering Technology Research Center","place":["Puyang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhui","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Institute of Hematology Southeast University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxu","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Puyang Oilfield General Hospital Affiliated to Henan Medical University","place":["Puyang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology, Puyang Oilfield General Hospital Affiliated to Henan Medical University","place":["Puyang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxue","family":"Ma","sequence":"additional","affiliation":[{"name":"Sanford Stem Cell Institute, Department of Medicine, Moores Cancer Center, University of California, San Diego","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41525-025-00465-9","article-title":"Pd-1 transcriptomic landscape across cancers and implications for immune checkpoint blockade outcome","volume":"10","author":"Chen","year":"2025","journal-title":"NPJ Genom Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009427","article-title":"Biomarker development for Pd-(L)1 axis inhibition: A consensus view from the Sitc biomarkers committee","volume":"12","author":"Monette","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00824-9","article-title":"Acquired resistance in cancer: Towards targeted therapeutic strategies","volume":"25","author":"Soragni","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-026-01424-9","article-title":"Adaptive resistance in cancer immunotherapy","volume":"23","author":"Yang","year":"2026","journal-title":"Cell Mol Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000004588","article-title":"Comparative predictive value of immunotherapy biomarkers: A systematic review and network meta-analysis","volume":"112","author":"Tuerhong","year":"2026","journal-title":"Int J Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2026.116711","article-title":"From prediction to precision: Biomarker discovery and predictive modeling for personalized immune checkpoint blockade therapy","volume":"239","author":"Wijnen","year":"2026","journal-title":"Eur J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov"},{"key":"B8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13045-021-01166-3","article-title":"Intratumor heterogeneity: The hidden barrier to immunotherapy against Msi tumors from the perspective of Ifn-gamma signaling and tumor-infiltrating lymphocytes","volume":"14","author":"Wu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor mutational burden as a predictor of immunotherapy response: Is more always better","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.007","article-title":"Tumor mutational burden for the prediction of Pd-(L)1 blockade efficacy in cancer: Challenges and opportunities","volume":"35","author":"Wang","year":"2024","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70654","article-title":"Clinical application of peripheral blood biomarkers for solid tumors","volume":"7","author":"Tu","year":"2026","journal-title":"MedComm (2020)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40364-026-00892-5","article-title":"Peripheral blood biomarkers for predicting response to Pd-1\/Pd-L1 inhibitors","volume":"14","author":"Chen","year":"2026","journal-title":"biomark Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47060428","article-title":"Revolution of circulating tumor DNA: From bench innovations to bedside implementations","volume":"47","author":"Yan","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16097","article-title":"Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine","volume":"115","author":"Bao","year":"2024","journal-title":"Cancer Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70257","article-title":"Blood based biomarkers for predicting treatment response to immune checkpoint inhibitors after Egfr-Tki resistance in non-small cell lung cancer","volume":"17","author":"Park","year":"2026","journal-title":"Thorac Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18111840","article-title":"Liquid biopsy biomarkers for predicting and monitoring immunotherapy response in lung cancer","volume":"18","author":"Serio","year":"2026","journal-title":"Cancers"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70684","article-title":"From theory to practice: Which biomarkers are ready for predicting response in advanced Hcc","volume":"46","author":"Decraecker","year":"2026","journal-title":"Liver Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1633487","article-title":"Applications and challenges of biomarker-based predictive models in proactive health management","volume":"13","author":"Zhao","year":"2025","journal-title":"Front Public Health"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-026-01616-8","article-title":"Confounding factors and biases abound when predicting molecular biomarkers from histological images","author":"Dawood","year":"2026","journal-title":"Nat BioMed Eng"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17122001","article-title":"Blood-based biomarkers as predictive and prognostic factors in immunotherapy-treated patients with solid tumors-currents and perspectives","volume":"17","author":"Kaczmarek","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.premed.2026.100032","article-title":"Advances in cancer biomarkers: Diagnostic, prognostic, and therapeutic implications","volume":"5","author":"Madhuranga","year":"2026","journal-title":"J Precis Medicine: Health Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","article-title":"Tumor biomarkers for diagnosis, prognosis and targeted therapy","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1186\/s40001-025-03003-6","article-title":"Emerging biomarkers for early cancer detection and diagnosis: Challenges, innovations, and clinical perspectives","volume":"30","author":"Zafar","year":"2025","journal-title":"Eur J Med Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.07.008","article-title":"Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications","volume":"43","author":"Dai","year":"2025","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.46883\/2023.25920995","article-title":"Biomarkers for response to anti-Pd-1\/anti-Pd-L1 immune checkpoint inhibitors: A large meta-analysis","volume":"37","author":"Mariam","year":"2023","journal-title":"Oncol (Williston Park)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2026.218359","article-title":"Emerging biomarkers in melanoma: Bridging molecular discovery and precision oncology","volume":"645","author":"Xu","year":"2026","journal-title":"Cancer Lett"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-026-01453-7","article-title":"Imireg: A lineage-resolved regulon signature unveiling immune engagement archetypes and predicting immunotherapy response across diverse cancers","volume":"10","author":"Lawal","year":"2026","journal-title":"NPJ Precis Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1709852","article-title":"Terminally exhausted Cd8(+) T cells in solid tumors: Biology, biomarker potential and translational tools for precision oncology","volume":"16","author":"Guo","year":"2025","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1798585","article-title":"Cd24 as an innate immune checkpoint in solid tumors: Biology, biomarker stratification, and therapeutic translation","volume":"17","author":"Zhou","year":"2026","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1454720","article-title":"Companion diagnostics and predictive biomarkers for Pd-1\/Pd-L1 immune checkpoint inhibitors therapy in malignant melanoma","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10051181","article-title":"Challenges and the evolving landscape of assessing blood-based Pd-L1 expression as a biomarker for anti-Pd-(L)1 immunotherapy","volume":"10","author":"Wang","year":"2022","journal-title":"Biomedicines"},{"key":"B32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s10238-024-01404-1","article-title":"Current status and progress of Pd-L1 detection: Guiding immunotherapy for non-small cell lung cancer","volume":"24","author":"Qi","year":"2024","journal-title":"Clin Exp Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2024.00278","article-title":"Predictive and prognostic biomarkers in cancer: Towards the precision medicine era","volume":"5","author":"Marletta","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087577","article-title":"Prognostic and predictive biomarkers in the era of immunotherapy for lung cancer","volume":"24","author":"Pabst","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061414","article-title":"Inflammatory cytokines and Ctdna are biomarkers for progression in advanced-stage melanoma patients receiving checkpoint inhibitors","volume":"12","author":"Pedersen","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2025.1002314","article-title":"The development and applications of circulating tumour cells, circulating tumour DNA and other emerging biomarkers for early cancer detection","volume":"6","author":"Thomas Junior","year":"2025","journal-title":"Explor Target Antitumor Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2026.102764","article-title":"Core regulatory mechanisms of the Pd-L1 axis and clinical strategies for immune escape and immunotherapy response in nasopharyngeal carcinoma","volume":"68","author":"Li","year":"2026","journal-title":"Transl Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006464","article-title":"Predictive biomarkers for Pd-1\/Pd-L1 checkpoint inhibitor response in Nsclc: An analysis of clinical trial and real-world data","volume":"11","author":"So","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-025-09105-7","article-title":"Pd-1\/Pd-L1 cancer immunotherapeutics reshape tumor microenvironment - Clinical evidence and molecular mechanisms for Ai-based precision medicine","volume":"68","author":"Lin","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1686521","article-title":"Prognostic significance of baseline systemic inflammation markers in Pd-L1-negative advanced non-small cell lung cancer patients treated with the Brics sequential regimen","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.cell.2022.01.008","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"185","author":"Morad","year":"2022","journal-title":"Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17162639","article-title":"Immune biomarkers for checkpoint blockade in solid tumors: Transitioning from tissue to peripheral blood monitoring and future integrated strategies","volume":"17","author":"Trontzas","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxaf010","article-title":"Peripheral immune biomarkers associated with response to adoptive cell therapy with tumor infiltrating lymphocytes","volume":"219","author":"Madsen","year":"2025","journal-title":"Clin Exp Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00473-5","article-title":"Pd-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27073192","article-title":"Integrating blood-based immune-inflammation biomarkers into artificial intelligence-driven prognostic models in oncology","volume":"27","author":"Dobrowolska-Szumowska","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2025-162","article-title":"Mechanistic insights into the immune biomarker of perioperative immune checkpoint inhibitors for non-small cell lung cancer","volume":"14","author":"Long","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218109","article-title":"Harnessing Il-2 without feeding the enemy: Modern strategies to overcome regulatory T cell expansion in cancer immunotherapy","volume":"635","author":"Ma","year":"2025","journal-title":"Cancer Lett"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-2025-76","article-title":"Circulating tumor DNA in lung cancer: A bibliometric analysis of studies published from 2001 to 2024","volume":"17","author":"Zhang","year":"2025","journal-title":"J Thorac Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"Esmo recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the Esmo precision medicine working group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2026.100470","article-title":"Radiogenomic approach combining Ct-based radiomics and liquid biopsy improves prognostic stratification in patients with advanced Nsclc","volume":"12","author":"Ranghiero","year":"2026","journal-title":"J Liq Biopsy"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-3643","article-title":"Longitudinal ctdna monitoring for postsurgical disease surveillance in patients with stage I to iiib melanoma","volume":"32","author":"Ansstas","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1186\/s12885-025-14755-z","article-title":"Baseline tumor burden predicts the efficacy of first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer: Results from 2 phase 3 randomized placebo-controlled trials","volume":"25","author":"He","year":"2025","journal-title":"BMC Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101621","article-title":"Advances and prospects of biomarkers for immune checkpoint inhibitors","volume":"5","author":"Yamaguchi","year":"2024","journal-title":"Cell Rep Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.121829","article-title":"Bispecific antibodies in glioblastoma: Mechanistic advances, delivery innovations, and translational challenges in overcoming immune escape","volume":"22","author":"Wang","year":"2025","journal-title":"Int J Med Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.006","article-title":"Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy","volume":"43","author":"Wang","year":"2025","journal-title":"Cancer Cell"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13040930","article-title":"Cd8+ T cell subsets as biomarkers for predicting checkpoint therapy outcomes in cancer immunotherapy","volume":"13","author":"Casalegno Garduno","year":"2025","journal-title":"Biomedicines"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14238610","article-title":"Systemic inflammatory biomarkers (interleukin-6, high-sensitivity c-reactive protein, and neutrophil-to-lymphocyte ratio) and prognosis in heart failure: A meta-analysis of prospective cohort studies","volume":"14","author":"Pah","year":"2025","journal-title":"J Clin Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04038-2","article-title":"Shared and specific blood biomarkers for multimorbidity","volume":"32","author":"Ornago","year":"2026","journal-title":"Nat Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1186\/s40001-025-03324-6","article-title":"Recent advances in biomarkers for detection and diagnosis of sepsis and organ dysfunction: A comprehensive review","volume":"30","author":"Chen","year":"2025","journal-title":"Eur J Med Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12943-025-02243-8","article-title":"Inflammation in cancer: Therapeutic opportunities from new insights","volume":"24","author":"Xie","year":"2025","journal-title":"Mol Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-026-00904-5","article-title":"Dynamic biomarkers in hormone receptor-positive\/her2-negative breast cancer trials: A new hope for precision oncology","volume":"12","author":"Di Grazia","year":"2026","journal-title":"NPJ Breast Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3558","article-title":"Methodological insights on biomarker-based patient selection: A review of scientific advice procedures at the European Medicines Agency","volume":"117","author":"Huber","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-026-03656-z","article-title":"Rewiring tumor cytokine networks to enhance immune checkpoint blockade: Mechanisms, engineering, and clinical translation","volume":"45","author":"Wang","year":"2026","journal-title":"J Exp Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010928","article-title":"Society for Immunotherapy of Cancer (Sitc) consensus statement on essential biomarkers for immunotherapy clinical protocols","volume":"13","author":"Cottrell","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1664443","article-title":"Optimizing early-phase immunotherapy trials: The role of biomarker enrichment strategies","volume":"16","author":"Catani","year":"2025","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02327-3","article-title":"Revitalizing T cells: Breakthroughs and challenges in overcoming T cell exhaustion","volume":"11","author":"Wu","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B67","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1186\/s12967-025-06583-3","article-title":"Targeting inflammation in cancer therapy: From mechanistic insights to emerging therapeutic approaches","volume":"23","author":"Bakrim","year":"2025","journal-title":"J Transl Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.001","article-title":"Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition","volume":"183","author":"Nabet","year":"2020","journal-title":"Cell"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer biomarkers: Emerging trends and clinical implications for personalized treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2025-900","article-title":"Circulating tumor DNA as prognostic markers of non-small cell lung cancer (nsclc): A systematic review and meta-analysis","volume":"14","author":"Chen","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32070373","article-title":"Role of circulating tumor DNA in adapting immunotherapy approaches in breast cancer","volume":"32","author":"Kumar","year":"2025","journal-title":"Curr Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17203327","article-title":"Circulating tumor DNA as a prognostic and predictive biomarker in lung cancer","volume":"17","author":"Dhillon","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B73","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27031569","article-title":"Circulating tumor DNA in melanoma: Advances in detection, clinical applications, and integration with emerging technologies","volume":"27","author":"Charbel","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1691229","article-title":"Prognostic value of baseline circulating tumor DNA levels in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis","volume":"17","author":"Liao","year":"2026","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.21037\/gs-24-115","article-title":"Baseline circulating tumor DNA predicts long-term survival outcomes for patients with early breast cancer","volume":"13","author":"Zhang","year":"2024","journal-title":"Gland Surg"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18111702","article-title":"Circulating tumor DNA as emerging predictive and prognostic biomarker in prostate cancer","volume":"18","author":"Thapa","year":"2026","journal-title":"Cancers"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-025-01621-x","article-title":"Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in her2-negative patients with advanced gastric cancer","volume":"28","author":"He","year":"2025","journal-title":"Gastric Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1802404","article-title":"Research progress in augmentation strategies for pd-1\/pd-l1 inhibitors in bladder cancer: From biological determinants to clinical applications","volume":"17","author":"Cheng","year":"2026","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005854","article-title":"Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: A systematic review","volume":"11","author":"Al-Showbaki","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.1646","article-title":"Early ctdna and survival in metastatic colorectal cancer treated with immune checkpoint inhibitors: A secondary analysis of the samco-prodige 54 randomized clinical trial","volume":"11","author":"Taieb","year":"2025","journal-title":"JAMA Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00254","article-title":"Multi-institutional study evaluating the role of early circulating tumor DNA dynamics during treatment with immune checkpoint inhibitors in patients with advanced-stage melanoma","volume":"10","author":"Ma","year":"2026","journal-title":"JCO Precis Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13027-025-00695-7","article-title":"Radiologists and treatment response assessment: Conventional and functional radiological criteria for predicting therapeutic response in virus-related and non-virus-related cancers","volume":"20","author":"Granata","year":"2025","journal-title":"Infect Agent Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-026-04495-2","article-title":"Circulating tumor DNA dynamics predict pathological response and guide therapy personalization in the neoadjuvant setting","volume":"17","author":"Ahmed","year":"2026","journal-title":"Discov Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0096-5","article-title":"Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab","volume":"1","author":"Bratman","year":"2020","journal-title":"Nat Cancer"},{"key":"B86","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s43856-024-00687-5","article-title":"Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers","volume":"4","author":"Barnett","year":"2024","journal-title":"Commun Med (Lond)"},{"key":"B87","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","article-title":"The role of neoantigens and tumor mutational burden in cancer immunotherapy: Advances, mechanisms, and perspectives","volume":"18","author":"Sun","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/hed.70297","article-title":"Tissue and blood-based tumor mutational burden predicts treatment response to pd-1 blockade in head and neck squamous cell carcinoma: A systematic review and meta-analysis","volume":"48","author":"Wang","year":"2026","journal-title":"Head Neck"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1681420","article-title":"Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab","volume":"15","author":"Horndalsveen","year":"2025","journal-title":"Front Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030480","article-title":"Evaluating tumour mutational burden as a key biomarker in personalized cancer immunotherapy: A pan-cancer systematic review","volume":"17","author":"Zgura","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1017\/pcm.2024.6","article-title":"The challenges and opportunities of applying tumour mutational burden analysis to precision cancer medicine","volume":"3","author":"Elbehi","year":"2025","journal-title":"Camb Prism Precis Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: Clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01754-x","article-title":"Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: The phase 2 B-F1rst trial","volume":"28","author":"Kim","year":"2022","journal-title":"Nat Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01933-w","article-title":"Atezolizumab versus chemotherapy in advanced or metastatic nsclc with high blood-based tumor mutational burden: Primary analysis of Bfast cohort C randomized phase 3 trial","volume":"28","author":"Peters","year":"2022","journal-title":"Nat Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: The mystic phase 3 randomized clinical trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41392-024-01938-6","article-title":"Circulating tumor cells: From new biological insights to clinical practice","volume":"9","author":"Gu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-024-10267-5","article-title":"Clinical applications of circulating tumor cells in patients with solid tumors","volume":"41","author":"Smit","year":"2024","journal-title":"Clin Exp Metastasis"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3390\/cells12222590","article-title":"Circulating tumor cells as predictive and prognostic biomarkers in solid tumors","volume":"12","author":"Capuozzo","year":"2023","journal-title":"Cells"},{"key":"B100","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00384-024-04785-7","article-title":"Circulating tumor DNA as a predictive biomarker for treatment response and survival in metastatic colorectal cancer","volume":"39","author":"Kou","year":"2024","journal-title":"Int J Colorectal Dis"},{"key":"B101","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41698-025-01174-3","article-title":"The prognostic and clinical utility of circulating tumor DNA in diffuse large B-cell lymphoma: A systematic review and meta-analysis","volume":"9","author":"Forghani","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202400438","article-title":"Heterogeneity landscape of circulating tumor cells in clinical utility","volume":"8","author":"Alam","year":"2025","journal-title":"Adv Ther"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1303335","article-title":"Research progress of Ctc, Ctdna, and Evs in cancer liquid biopsy","volume":"14","author":"Wang","year":"2024","journal-title":"Front Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013381","article-title":"Pd-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with hepatocellular carcinoma receiving Pd-(L)1 blockade and targeted therapy","volume":"14","author":"Gong","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B105","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12943-025-02400-z","article-title":"Overcoming resistance to anti-Pd-L1 immunotherapy: Mechanisms, combination strategies, and future directions","volume":"24","author":"Mandal","year":"2025","journal-title":"Mol Cancer"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-026-15733-9","article-title":"Pretreatment clinical and hematological predictors of efficacy and immune-related adverse events in patients with advanced non-small cell lung cancer receiving first-line chemotherapy combined with immune checkpoint inhibitors","volume":"26","author":"Matsuura","year":"2026","journal-title":"BMC Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1605976","article-title":"Ldh and glycolytic activity as predictors of immunotherapy response in gastric cancer: A systematic review and meta-analysis","volume":"16","author":"Zhu","year":"2025","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00873-1","article-title":"Biomarker prediction of immunotherapy response in breast cancer: From single markers to multi-omics integration","volume":"12","author":"Sanjari Moghaddam","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70412","article-title":"The role of immune checkpoint inhibitors in cancer therapy: Mechanism and therapeutic advances","volume":"6","author":"Chen","year":"2025","journal-title":"MedComm (2020)"},{"key":"B110","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s12672-025-04361-7","article-title":"Immune checkpoint blockade in cancer: Current insights and future horizons","volume":"17","author":"Saman","year":"2026","journal-title":"Discov Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.04.008","article-title":"Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer","volume":"42","author":"Dyikanov","year":"2024","journal-title":"Cancer Cell"},{"key":"B112","doi-asserted-by":"publisher","first-page":"15282","DOI":"10.1038\/s41598-023-42522-2","article-title":"Risk predict model using multi-drug resistant organism infection from neuro-Icu patients: A retrospective cohort study","volume":"13","author":"Jiang","year":"2023","journal-title":"Sci Rep"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-675","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio (Nlr) and platelet-to-lymphocyte ratio (Plr) in second-line immunotherapy for patients with non-small cell lung cancer","volume":"14","author":"Knetki-Wroblewska","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.70407","article-title":"The evaluation of diagnostic, prognostic, and predictive role of hematologic inflammatory indices Nlr, Plr, and Lmr in common solid tumors","volume":"8","author":"Arianmanesh","year":"2025","journal-title":"Cancer Rep (Hoboken)"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1732790","article-title":"Platelet-to-lymphocyte ratio for prognostication in immune checkpoint inhibitor-treated cancer patients: A meta-analysis of 13027 patients highlighting nivolumab-responsive renal cell carcinoma","volume":"17","author":"Wang","year":"2026","journal-title":"Front Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2025.2586257","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lactate dehydrogenase level in melanoma patients treated with immune checkpoint inhibitors","volume":"43","author":"Wijaya","year":"2025","journal-title":"Cancer Invest"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-026-02584-w","article-title":"Regulatory T cells in cancer and inflammation","volume":"11","author":"Yang","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1371559","article-title":"Circulating T cells: A promising biomarker of anti-Pd-(L)1 therapy","volume":"15","author":"Hou","year":"2024","journal-title":"Front Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1449","article-title":"The first-week proliferative response of peripheral blood Pd-1(+)Cd8(+) T cells predicts the response to anti-Pd-1 therapy in solid tumors","volume":"25","author":"Kim","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-Pd-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-70751-2","article-title":"Pd-1 antibody-bound progenitor-exhausted Cd8(+) T cells in lymph nodes boost Pd-1-blockade anti-tumor immunity in gastrointestinal cancer","volume":"17","author":"Nose","year":"2026","journal-title":"Nat Commun"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0223-7","article-title":"Precursor exhausted T cells: Key to successful immunotherapy","volume":"20","author":"Kallies","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-immunol-090222-110914","article-title":"T cell exhaustion","volume":"42","author":"Baessler","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00262-025-04086-0","article-title":"High baseline Pd-1+ Cd8 T cells and Tigit+ Cd8 T cells in circulation associated with response to Pd-1 blockade in patients with non-small cell lung cancer","volume":"74","author":"Dutta","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.07.009","article-title":"Cd4(+) T cells in antitumor immunity","volume":"10","author":"Montauti","year":"2024","journal-title":"Trends Cancer"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.4110\/in.2023.23.e41","article-title":"The role of Cd4 T cell help in Cd8 T cell differentiation and function during chronic infection and cancer","volume":"23","author":"Topchyan","year":"2023","journal-title":"Immune Netw"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105409","article-title":"Dendritic cell-driven immune rebalancing as a systemic regulator of tumor and neurodegenerative microenvironments","volume":"225","author":"Zhao","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.05.023","article-title":"The tissue-resident regulatory T cell pool is shaped by transient multi-tissue migration and a conserved residency program","volume":"57","author":"Burton","year":"2024","journal-title":"Immunity"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk3248","article-title":"Regulatory T cells constrain T cells of shared specificity to enforce tolerance during infection","volume":"387","author":"Klawon","year":"2025","journal-title":"Science"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02533-z","article-title":"Cytotoxic Cd4(+) T cells: Origin, biological functions, diseases and therapeutic targets","volume":"11","author":"Lai","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1623436","article-title":"Targeting myeloid cells to improve cancer immune therapy","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1749965","article-title":"Targeting Mdscs in cancer: Emerging immunotherapeutic and metabolic strategies","volume":"17","author":"Dash","year":"2026","journal-title":"Front Immunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1403771","article-title":"Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy: Systematic review and meta-analysis","volume":"15","author":"Moller","year":"2024","journal-title":"Front Immunol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (Mdscs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol Cancer"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2026-015830","article-title":"Expert opinion on burning questions in cancer myeloid cell biology","volume":"14","author":"Guerriero","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1823338","article-title":"Biomarkers for predicting immunotherapy response and resistance in glioblastoma","volume":"17","author":"Kim","year":"2026","journal-title":"Front Immunol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00262-022-03221-5","article-title":"Dynamic peripheral blood immune cell markers for predicting the response of patients with metastatic cancer to immune checkpoint inhibitors","volume":"72","author":"Wei","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1096","article-title":"Circulating tumor DNA assessment for treatment monitoring adds value to Psa in metastatic castration-resistant prostate cancer","volume":"30","author":"Sweeney","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.09.109","article-title":"Predictive biomarkers for immunotherapy in lung cancer: Perspective from the International Association for the Study of Lung Cancer Pathology Committee","volume":"17","author":"Mino-Kenudson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1418580","article-title":"Immunotherapy revolutionizing brain metastatic cancer treatment: Personalized strategies for transformative outcomes","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11061768","article-title":"Clinical significance of Pd-L1 status in circulating tumor cells for cancer management during immunotherapy","volume":"11","author":"Strati","year":"2023","journal-title":"Biomedicines"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.467","article-title":"Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-Pd-1 therapy in metastatic melanoma","volume":"114","author":"Diem","year":"2016","journal-title":"Br J Cancer"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1482746","article-title":"Prognostic value of inflammatory markers Nlr, Plr, Lmr, Dnlr, Anc in melanoma patients treated with immune checkpoint inhibitors: A meta-analysis and systematic review","volume":"15","author":"Ou","year":"2024","journal-title":"Front Immunol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41392-025-02326-4","article-title":"Regulatory T cells in homeostasis and disease: Molecular mechanisms and therapeutic potential","volume":"10","author":"Wang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B146","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.cytogfr.2025.10.009","article-title":"Natural killers or natural regulators? Dual roles of Nk cells in checkpoint immunotherapy","volume":"86","author":"Ma","year":"2025","journal-title":"Cytokine Growth Factor Rev"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.145847","article-title":"The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"101","author":"Artz","year":"2016","journal-title":"Haematologica"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-026-07924-6","article-title":"Tumor-infiltrating lymphocytes demonstrate potent anti-tumor efficacy and synergize with Pd-1 blockade in bladder cancer","volume":"24","author":"Huang","year":"2026","journal-title":"J Transl Med"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2025.101076","article-title":"Harnessing Tcr repertoires: Predictive insights and therapeutic monitoring in cancer immunotherapy","volume":"28","author":"Chiffelle","year":"2025","journal-title":"Immunooncol Technol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101882","article-title":"Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy","volume":"6","author":"Chin","year":"2025","journal-title":"Cell Rep Med"},{"key":"B151","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.abst.2025.03.001","article-title":"Biomarkers in immunology: Their impact on immune function and response","volume":"7","author":"Kaushik","year":"2025","journal-title":"Adv biomark Sci Technol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1677778","article-title":"Low rather than high interleukin-6 levels are associated with immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"16","author":"Les","year":"2025","journal-title":"Front Immunol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5535578","article-title":"Il-6 promotes the proliferation and immunosuppressive function of myeloid-derived suppressor cells via the Mapk signaling pathway in bladder cancer","volume":"2021","author":"Zheng","year":"2021","journal-title":"BioMed Res Int"},{"key":"B155","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41392-025-02331-7","article-title":"Cancer cachexia: Molecular basis and therapeutic advances","volume":"11","author":"Tan","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B156","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41392-025-02178-y","article-title":"Deep insight into cytokine storm: From pathogenesis to treatment","volume":"10","author":"Nie","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3892\/br.2020.1276","article-title":"Types of acute phase reactants and their importance in vaccination","volume":"12","author":"Khalil","year":"2020","journal-title":"BioMed Rep"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-23-240","article-title":"C-reactive protein and lactate dehydrogenase serum levels potentially predict the response to checkpoint inhibitors in patients with advanced non-small cell lung cancer","volume":"15","author":"Wei","year":"2023","journal-title":"J Thorac Dis"},{"key":"B159","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1186\/s12885-025-14894-3","article-title":"Systemic inflammation biomarkers can identify high tumor mutation burden in lung adenocarcinoma","volume":"25","author":"Fang","year":"2025","journal-title":"BMC Cancer"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47121003","article-title":"Evaluating the Crp interactome: Insights into possible novel roles in cellular signaling and tumorigenicity","volume":"47","author":"Gerhardt","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106628","article-title":"Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors","volume":"85","author":"Yao","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2024.01.004","article-title":"The current and future of biomarkers of immune related adverse events","volume":"50","author":"Bracamonte-Baran","year":"2024","journal-title":"Rheum Dis Clin North Am"},{"key":"B163","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-018-0578-4","article-title":"Lessons learned from the blockade of immune checkpoints in cancer immunotherapy","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1323797","article-title":"The implication of targeting Pd-1:Pd-L1 pathway in treating sepsis through immunostimulatory and anti-inflammatory pathways","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.12.031","article-title":"A quantitative systems pharmacology workflow toward optimal design and biomarker stratification of atopic dermatitis clinical trials","volume":"153","author":"Go","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18030391","article-title":"Real-time therapy response monitoring using surface biomarkers on circulating tumor cells","volume":"18","author":"Andhari","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B168","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41698-025-00886-w","article-title":"Multi-omics in immunotherapy research for Hnscc: Present situation and future perspectives","volume":"9","author":"Liu","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-026-02631-6","article-title":"Multi-omics and artificial intelligence for precision drug discovery and potential clinical applications","volume":"11","author":"Liu","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.32604\/or.2024.056565","article-title":"Exploring the therapeutic potential of precision T-cell receptors (Tcrs) in targeting Kras G12d cancer through in vitro development","volume":"32","author":"Zheng","year":"2024","journal-title":"Oncol Res"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1267918","article-title":"The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment","volume":"14","author":"Luo","year":"2023","journal-title":"Front Immunol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1111\/imr.70136","article-title":"The T cell receptor: Molecular sensor, therapeutic mediator and probabilistic driver of adaptive immunity","volume":"340","author":"Schober","year":"2026","journal-title":"Immunol Rev"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1819997","article-title":"Stable global repertoire architecture masks short-term clonal remodeling in intratumoral Tcr repertoires","volume":"17","author":"Pedersen","year":"2026","journal-title":"Front Immunol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41698-025-01223-x","article-title":"Quantitative profiling of intratumor immune heterogeneity identifies loss of immune diversity as a hallmark of cancer progression","volume":"10","author":"Lu","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18030537","article-title":"Extracellular vesicles in cancer: Mechanistic insights and clinical applications","volume":"18","author":"Alhumaydhi","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1853671","article-title":"Extracellular vesicle biomarkers: Current status and future perspectives as novel tools in liquid biopsy","volume":"17","author":"Huang","year":"2026","journal-title":"Front Immunol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1603855","article-title":"Exosomal Pd-L1 detection in cancer predictive biomarker for response to immune checkpoint blockade therapy","volume":"16","author":"Kansha","year":"2025","journal-title":"Front Immunol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41698-022-00287-3","article-title":"Small extracellular vesicle Pd-L1 in cancer: The knowns and unknowns","volume":"6","author":"Yu","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12964-025-02630-0","article-title":"The interplay between the extracellular matrix and extracellular vesicle-associated Micrornas","volume":"24","author":"Wu","year":"2026","journal-title":"Cell Commun Signal"},{"key":"B180","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1186\/s12951-025-03768-2","article-title":"Advances of extracellular vesicles isolation and detection frontier technology: From heterogeneity analysis to clinical application","volume":"23","author":"Li","year":"2025","journal-title":"J Nanobiotechnol"},{"key":"B181","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","article-title":"Extracellular vesicles as tools and targets in therapy for diseases","volume":"9","author":"Kumar","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2895","article-title":"Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors","volume":"3","author":"Nomura","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc3421","article-title":"Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy","volume":"369","author":"Mager","year":"2020","journal-title":"Science"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2026.2652476","article-title":"Modulating the gut microbiota to enhance immune checkpoint inhibitor efficacy in colorectal cancer: Mechanisms, therapeutic strategies, and clinical perspectives","volume":"18","author":"Chen","year":"2026","journal-title":"Gut Microbes"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"B186","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-Pd-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2018.11.003","article-title":"Contamination in low microbial biomass microbiome studies: Issues and recommendations","volume":"27","author":"Eisenhofer","year":"2019","journal-title":"Trends Microbiol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01695-5","article-title":"Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma","volume":"28","author":"Lee","year":"2022","journal-title":"Nat Med"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1732079","article-title":"Artificial intelligence-enabled multi-omics biomarkers for immune checkpoint blockade: Mechanisms, predictive modeling, and clinical translation","volume":"17","author":"Wang","year":"2026","journal-title":"Front Immunol"},{"key":"B191","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10238-025-01902-w","article-title":"Beyond single biomarkers: Multi-omics strategies to predict immunotherapy outcomes in blood cancers","volume":"25","author":"Pirouzbakht","year":"2025","journal-title":"Clin Exp Med"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110096","article-title":"Elucidating immune-related gene transcriptional programs via factorization of large-scale Rna-profiles","volume":"27","author":"He","year":"2024","journal-title":"iScience"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1007\/s10791-026-09974-2","article-title":"A modular transcriptomic signature paired with machine learning reveals core immune pathways in sepsis diagnosis","volume":"29","author":"Johari","year":"2026","journal-title":"Discover Computing"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2025.106245","article-title":"Epigenetic biomarkers of inflammation in studies on mental health: Current applications, limitations, and future directions","volume":"133","author":"Schalkwijk","year":"2026","journal-title":"Brain Behav Immun"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.72452","article-title":"Multi-omics biomarkers from variant to clinic: A systematic review and meta-analysis of evidence, Ai\/Ml, governance, equity, and real-world implementation across global health systems","volume":"9","author":"Das","year":"2026","journal-title":"Health Sci Rep"},{"key":"B196","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s12032-025-03002-x","article-title":"Immune profiling in oncology: Bridging the gap between technology and treatment","volume":"42","author":"Ravi","year":"2025","journal-title":"Med Oncol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00449-x","article-title":"Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy","volume":"18","author":"Gohil","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2025.06.004","article-title":"Next-generation immune profiling - Beyond blood cancer cells","volume":"31","author":"Unger","year":"2025","journal-title":"Trends Mol Med"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1064106","article-title":"Mass cytometry and single-cell Rna sequencing reveal immune cell characteristics of active and inactive phases of Crohn's disease","volume":"9","author":"Lin","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-026-01450-8","article-title":"Challenges and potential of using digital biomarkers in healthcare and clinical trials","volume":"6","author":"Lieberwirth","year":"2026","journal-title":"Commun Med (Lond)"},{"key":"B201","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jmoldx.2025.04.003","article-title":"Clinical bioinformatician body of knowledge-clinical laboratory regulation and data security core: A report of the Association for Molecular Pathology","volume":"27","author":"Schmidt","year":"2025","journal-title":"J Mol Diagn"},{"key":"B202","doi-asserted-by":"publisher","first-page":"101630","DOI":"10.1016\/j.jpha.2026.101630","article-title":"Bridging realms: Artificial intelligence integrates omics, generative models, and traditional medicine for anticancer drug innovation","author":"Li","year":"2026","journal-title":"J Pharm Anal"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2026.104679","article-title":"Physics-inspired explainable ai for mechanistic and decision support in drug discovery","volume":"31","author":"Lavecchia","year":"2026","journal-title":"Drug Discov Today"},{"key":"B204","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1186\/s12885-025-14523-z","article-title":"Pre-treatment peripheral blood tcr repertoire as a predictor of response in patients with nsclc treated with immunochemotherapy","volume":"25","author":"Yang","year":"2025","journal-title":"BMC Cancer"},{"key":"B205","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s44276-024-00096-0","article-title":"Small extracellular vesicles as biomarkers of response in recurrent\/metastatic hnscc patients treated with immunotherapy","volume":"2","author":"Zandberg","year":"2024","journal-title":"BJC Rep"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1395332","article-title":"Exosomal pd-l1 in cancer and other fields: Recent advances and perspectives","volume":"15","author":"Lu","year":"2024","journal-title":"Front Immunol"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aec2358","article-title":"Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer","volume":"18","author":"Sun","year":"2026","journal-title":"Sci Transl Med"},{"key":"B208","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1042\/EBC20253017","article-title":"Single-cell rna sequencing: Enhancing the predictive accuracy of tumor immunotherapy efficacy","volume":"69","author":"Zhou","year":"2025","journal-title":"Essays Biochem"},{"key":"B209","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12882-024-03754-0","article-title":"Single-cell rna sequencing analysis of peripheral blood mononuclear cells in pd-1-induced renal toxicity in patients with lung cancer","volume":"25","author":"Liu","year":"2024","journal-title":"BMC Nephrol"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1551017","article-title":"An exploratory single-cell analysis of peripheral blood mononuclear cells from vedolizumab-treated Crohn's disease patients identifies response-associated differences among the plasmacytoid dendritic cells and classical monocytes","volume":"16","author":"Li Yim","year":"2025","journal-title":"Front Immunol"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098422","article-title":"Single-cell analysis in immuno-oncology","volume":"24","author":"Christodoulou","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering12111215","article-title":"Peripheral blood tcr clonotype diversity as a biomarker for colorectal cancer","volume":"12","author":"Zhu","year":"2025","journal-title":"Bioengineering (Basel)"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-026-01405-y","article-title":"T cell adaptation in chronic infections and tumors","volume":"23","author":"Luxenburger","year":"2026","journal-title":"Cell Mol Immunol"},{"key":"B215","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1186\/s12885-025-13426-3","article-title":"The prognostic value of a laboratory cachexia score (lcas) defined by ldh, crp and albumin in patients with advanced lung cancer","volume":"25","author":"Thompson","year":"2025","journal-title":"BMC Cancer"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078378","article-title":"Tripod+ai statement: Updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11162244","article-title":"Optimizing clinical decision making with decision curve analysis: Insights for clinical investigators","volume":"11","author":"Piovani","year":"2023","journal-title":"Healthcare (Basel)"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2251830","article-title":"Predictive overfitting in immunological applications: Pitfalls and solutions","volume":"19","author":"Gygi","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B219","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","article-title":"Advances in molecular pathology and therapy of non-small cell lung cancer","volume":"10","author":"Huang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18050858","article-title":"Advances in functional and metabolic imaging for early tumor treatment response and resistance evaluation: A review","volume":"18","author":"Gan","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1016\/j.resplu.2025.101126","article-title":"Dynamic biomarker trajectories in the first 72 h after infarct-related cardiac arrest: A novel approach to early risk stratification","volume":"26","author":"Mohsennia","year":"2025","journal-title":"Resusc Plus"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00063","article-title":"Factors associated with implementation of biomarker testing and strategies to improve its clinical uptake in cancer care: Systematic review using theoretical domains framework","volume":"9","author":"Salam","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"B223","doi-asserted-by":"publisher","first-page":"8161","DOI":"10.1038\/s41467-025-63538-4","article-title":"Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma","volume":"16","author":"Wang","year":"2025","journal-title":"Nat Commun"},{"key":"B224","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s43556-025-00340-0","article-title":"Multi-omics strategies for biomarker discovery and application in personalized oncology","volume":"6","author":"Jiang","year":"2025","journal-title":"Mol BioMed"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03398-5","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data","volume":"31","author":"Yoo","year":"2025","journal-title":"Nat Med"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1038\/s44386-025-00013-6","article-title":"The ai drug revolution needs a revolution","volume":"2","author":"Jacobson","year":"2025","journal-title":"NPJ Drug Discov"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2024.2403639","article-title":"Data-centric challenges with the application and adoption of artificial intelligence for drug discovery","volume":"19","author":"Ghislat","year":"2024","journal-title":"Expert Opin Drug Discov"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2026.115026","article-title":"A comprehensive review of explainable artificial intelligence in healthcare methods, evaluation, and clinical integration","volume":"29","author":"Zhang","year":"2026","journal-title":"iScience"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18020327","article-title":"Integrated and comprehensive diagnostics: An emerging paradigm in precision oncology","volume":"18","author":"Das","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1002\/sim.10230","article-title":"Combining biomarkers to improve diagnostic accuracy in detecting diseases with group-tested data","volume":"43","author":"Yang","year":"2024","journal-title":"Stat Med"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13411","article-title":"Leveraging patient-centric sampling for clinical drug development and decentralized clinical trials: Promise to reality","volume":"15","author":"Maass","year":"2022","journal-title":"Clin Transl Sci"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-026-02553-1","article-title":"Regulating complexity in ai-enabled omics and multi-omics technologies for precision medicine","volume":"9","author":"Welzel","year":"2026","journal-title":"NPJ Digit Med"},{"key":"B233","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41591-019-0382-x","article-title":"Genomic correlates of response to immune checkpoint blockade","volume":"25","author":"Keenan","year":"2019","journal-title":"Nat Med"},{"key":"B234","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1186\/s40001-025-03196-w","article-title":"Artificial intelligence in healthcare and medicine: Clinical applications, therapeutic advances, and future perspectives","volume":"30","author":"Fahim","year":"2025","journal-title":"Eur J Med Res"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.1616","article-title":"Biomarker discovery and validation: Statistical considerations","volume":"16","author":"Ou","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-2312","article-title":"Broad utility of ultrasensitive analysis of ctdna dynamics across solid tumors treated with immunotherapy","volume":"32","author":"Garralda","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S542704","article-title":"Clinical management of circulating tumor dna in breast cancer: Detection, prediction, and monitoring","volume":"17","author":"Lu","year":"2025","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"B238","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1186\/s12876-025-04370-4","article-title":"Diagnostic value of neutrophil\/lymphocyte ratio, platelet\/lymphocyte ratio and systemic immune-inflammation index for predicting the severity of acute pancreatitis","volume":"25","author":"Salehi","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61091530","article-title":"Prognostic value of inflammatory and metabolic biomarkers in icu-admitted trauma patients: A retrospective cohort study","volume":"61","author":"Celik","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-026-02050-9","article-title":"Molecular and cellular landscapes of the immune microenvironment and multiomic biomarker-sets in platinum-resistant recurrent ovarian cancers","volume":"19","author":"Feng","year":"2026","journal-title":"J Ovarian Res"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-04007-8","article-title":"Single-cell sequencing: Accurate disease detection","volume":"28","author":"Wang","year":"2026","journal-title":"Clin Transl Oncol"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013285","article-title":"Advancing adoptive t cell therapy in ovarian cancer: Barriers, innovations, and emerging platforms","volume":"14","author":"Santos","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1002\/sim.70275","article-title":"Adaptive biomarker-based design for early phase clinical trials","volume":"44","author":"Serra","year":"2025","journal-title":"Stat Med"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27042030","article-title":"A practical roadmap for clinical translation of metabolic biomarkers: A review","volume":"27","author":"Kim","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26031235","article-title":"Targeting the pd-1\/pd-l1 signaling pathway for cancer therapy: Focus on biomarkers","volume":"26","author":"Strati","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12092146","article-title":"The importance of predictive biomarkers and their correlation with the response to immunotherapy in solid tumors-impact on clinical practice","volume":"12","author":"Mihaila","year":"2024","journal-title":"Biomedicines"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17182981","article-title":"Cancer biomarkers: Reflection on recent progress, emerging innovations, and the clinical horizon","volume":"17","author":"Qoronfleh","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13020333","article-title":"Biomarkers as prognostic predictors and therapeutic guide in critically ill patients: Clinical evidence","volume":"13","author":"Mendez Hernandez","year":"2023","journal-title":"J Pers Med"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1854718","article-title":"Liquid biopsy, multi-cancer early detection, and artificial intelligence: New frontiers in cancer screening from a technological and immunological perspective","volume":"17","author":"Wu","year":"2026","journal-title":"Front Immunol"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5332","article-title":"Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0043-5","article-title":"Circulating tumor DNA and liquid biopsy in oncology","volume":"1","author":"Cescon","year":"2020","journal-title":"Nat Cancer"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2025.06.008","article-title":"Analytical validation of blood-derived tumor mutation burden (Btmb) assays: A joint consensus recommendation of the Bloodpac Btmb Analytical Validation Working Group","volume":"27","author":"Baden","year":"2025","journal-title":"J Mol Diagn"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104564","article-title":"Bith, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer","volume":"91","author":"Fan","year":"2023","journal-title":"EBioMedicine"},{"key":"B254","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41392-021-00817-8","article-title":"Circulating tumor cells: Biology and clinical significance","volume":"6","author":"Lin","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.116050","article-title":"International expert consensus on the clinical integration of circulating tumor cells in solid tumors","volume":"231","author":"Nicolo","year":"2025","journal-title":"Eur J Cancer"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27517","article-title":"Association of neutrophil-to-lymphocyte ratio and risk of cardiovascular and all-cause mortality in hypertension patients","volume":"10","author":"Hong","year":"2024","journal-title":"Heliyon"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081508","article-title":"Prognostic biomarkers of systemic inflammation in non-small cell lung cancer: A narrative review of challenges and opportunities","volume":"16","author":"Stares","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-026-02705-5","article-title":"Pancreatic ductal adenocarcinoma: Integrating molecular insights for targeted interventions","volume":"11","author":"Nagaraju","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v16.i5.104138","article-title":"Functional heterogeneity and clinical implications of Cd4+ T cell subtypes in high-grade serous ovarian carcinoma","volume":"16","author":"Zhang","year":"2025","journal-title":"World J Clin Oncol"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S485642","article-title":"Emerging role of Mdscs as novel biomarkers and therapeutic targets for cancer immunotherapy","volume":"14","author":"Silva-Romeiro","year":"2025","journal-title":"Immunotargets Ther"},{"key":"B261","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41698-025-01036-y","article-title":"Circulating T-cell receptor repertoire for cancer early detection","volume":"9","author":"Li","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvad176","article-title":"Extracellular vesicles as liquid biopsy biomarkers across the cancer journey: From early detection to recurrence","volume":"70","author":"Rayamajhi","year":"2024","journal-title":"Clin Chem"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-026-03068-6","article-title":"Scalable single-cell total RNA sequencing unifies coding and noncoding transcriptomics","author":"Isakova","year":"2026","journal-title":"Nat Biotechnol"},{"key":"B264","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s12672-025-04324-y","article-title":"Single-cell transcriptomic profiling and machine learning identify S-nitrosylation-associated Lamc2 as a key prognostic driver in pancreatic cancer","volume":"17","author":"Yang","year":"2025","journal-title":"Discov Oncol"},{"key":"B265","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12874-025-02703-1","article-title":"Machine learning models explanations as interpretations of evidence: A theoretical framework of explainability and its implications on high-stakes biomedical decision-making","volume":"25","author":"Rizzo","year":"2025","journal-title":"BMC Med Res Methodol"},{"key":"B266","doi-asserted-by":"publisher","first-page":"39269","DOI":"10.1038\/s41598-025-22972-6","article-title":"Machine learning prediction model for medical environment comfort based on Shap and Lime interpretability analysis","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-026-01287-1","article-title":"Artificial intelligence-based biomarkers for the diagnosis and treatment of neurological conditions: A narrative review","volume":"19","author":"Ben-Jaafar","year":"2026","journal-title":"Mol Brain"},{"key":"B268","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s44178-025-00167-3","article-title":"Application of biomarkers in the assessment and treatment of cancer-related fatigue","volume":"4","author":"Hu","year":"2025","journal-title":"Holistic Integr Oncol"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-594","article-title":"Predictive biomarkers for immune checkpoint efficacy: Is multi-omics breaking the deadlock","volume":"13","author":"Mogenet","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.2147\/LCTT.S539777","article-title":"Integrated multi-omics approaches for predicting immune checkpoint inhibitor response in Nsclc - Insights from genomics, proteomics, and metabolomics","volume":"16","author":"Elayeh","year":"2025","journal-title":"Lung Cancer (Auckl)"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.1016\/j.btre.2025.e00938","article-title":"Integrating multi-omics data: Methods and applications in human complex diseases","volume":"48","author":"Sibilio","year":"2025","journal-title":"Bio\/Technol Rep (Amst)"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1186\/s41512-026-00227-w","article-title":"Methods for evaluating models, tests and biomarkers (Memtab): Abstracts from the 7(th) International Conference, Memtab 2025","volume":"10","author":"Riley","year":"2026","journal-title":"Diagn Progn Res"},{"key":"B273","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41746-025-01471-y","article-title":"Convergence of evolving artificial intelligence and machine learning techniques in precision oncology","volume":"8","author":"Fountzilas","year":"2025","journal-title":"NPJ Digit Med"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-082505","article-title":"Probast+Ai: An updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods","volume":"388","author":"Moons","year":"2025","journal-title":"BMJ"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01772-9","article-title":"Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: Decide-Ai","volume":"28","author":"Vasey","year":"2022","journal-title":"Nat Med"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1034-x","article-title":"Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: The Consort-Ai extension","volume":"26","author":"Liu","year":"2020","journal-title":"Nat Med"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.88647","article-title":"Predictive biomarkers in cancer immunotherapy: A narrative review across selected solid tumors","volume":"17","author":"Puntambekar","year":"2025","journal-title":"Cureus"},{"key":"B278","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11060-025-05329-x","article-title":"Diagnostic and predictive molecular biomarkers in brain tumors across the lifespan: An age-stratified consensus statement","volume":"176","author":"Mastronuzzi","year":"2025","journal-title":"J Neuro-Oncol"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-026-03121-0","article-title":"Understanding heterogeneity in prevalence meta-analyses: From structural incompatibility to statistical variation","volume":"15","author":"Bigna","year":"2026","journal-title":"Syst Rev"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2012.3.3.7","article-title":"Threats to validity in retrospective studies","volume":"3","author":"Tofthagen","year":"2012","journal-title":"J Adv Pract Oncol"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03352-5","article-title":"Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations","volume":"31","author":"Orcutt","year":"2025","journal-title":"Nat Med"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.3390\/cells14100732","article-title":"Modeling tumor microenvironment complexity in vitro: Spheroids as physiologically relevant tumor models and strategies for their analysis","volume":"14","author":"Shah","year":"2025","journal-title":"Cells"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2026.1720615","article-title":"Technological innovation in healthcare: Challenges, opportunities and impact on sustainability","volume":"8","author":"Vallet-Regi","year":"2026","journal-title":"Front Digit Health"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70377","article-title":"Use of biomarkers in drug development for regulatory purposes","volume":"18","author":"Schuck","year":"2025","journal-title":"Clin Transl Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1924506\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:29:46Z","timestamp":1787826586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1924506\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":284,"alternative-id":["10.3389\/fimmu.2026.1924506"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1924506","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"1924506"}}